Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.71 |
| ▸ | CA5A | P35218 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine SCHEMBL3047091 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL12018219 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL12018226 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL3655059 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL13046076 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL12232219 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL13046078 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL14031844 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL12019517 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL1981701 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 949 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| WO-2026102302-A1 | POLYNUCLEOTIDES CONTAINING A MODIFIED 3'-REGION | MODERNATX, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| CN-117858949-A | RNAi agents for inhibiting expression of mucin 5AC (MUC 5 AC), compositions thereof, and methods of use thereof | 箭头药业股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117467726-A | Preparation method of purine nucleoside | 天津凯莱英生物科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-117440817-A | RNAi agents for inhibiting expression of advanced glycation end product receptors, compositions and methods of use thereof | 箭头药业股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-116801885-A | RNAi agents for inhibiting DUX4 expression, compositions and methods of use | 箭头药业股份有限公司 | 2023-09-22 | — | — | CN | claimed |
| US-11553713-B2 | Polyalcohol, carbohydrate, nucleobase and nucleotide compositions and uses thereof | Zhang, Chunbo (US) | 2023-01-17 | — | — | US | claimed |
| CN-113549076-B | Polysubstituted purine compound and preparation method and application thereof | 中国药科大学 | 2022-12-06 | — | — | CN | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| US-6372725-B1 | VIRICIDES, ANTICARCINOGENIC AND ANTITUMOR AGENTS; SIDE EFFECT REDUCTION | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2002-04-16 | — | — | US | claimed |
| EP-0817790-B1 | SPECIFIC LIPID CONJUGATES OF NUCLEOSIDE DIPHOSPHATES AND THEIR USE AS DRUGS | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2001-11-14 | — | — | EP | claimed |
| US-6025343-A | Lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs | ROCHE DIAGNOSTICS GMBH (DE) | 2000-02-15 | — | — | US | claimed |
| US-6017896-A | Purine nucleoside phosphorylase gene therapy for human malignancy | UNIVERSITY OF ALABAMA RESEARCH FOUNDATION AND SOUTHERN RESEARCH INSTITUTE (US) | 2000-01-25 | — | — | US | claimed |
| EP-0670845-B1 | PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE | SCHERING AG (DE) | 1998-01-14 | — | — | EP | claimed |
| US-5696255-A | Process for the production of 2-fluoropurine derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | claimed |
| US-5602246-A | Process for the preparation of fludarabine or fludarabine phosphate from guanosine | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-02-11 | — | — | US | claimed |
| EP-0670845-A1 | PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-09-13 | — | — | EP | claimed |
| WO-1994012514-A1 | PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-06-09 | — | — | WO | claimed |
| US-4751224-A | FORSKOLIN DERIVATIVES; ANTIAGGLOMERANTS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1988-06-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | LMNA 1661/4885NT5E 1487/4885HIF1A 3160/4885 |
| US-11553713-B2 | Polyalcohol, carbohydrate, nucleobase and nucleotide compositions and uses thereof | PNP, RNMT, RNGTT | LMNA 989/4885NT5E 19/4885HIF1A 4735/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | LMNA 2736/4885NT5E 4039/4885HIF1A 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.